Axillary Treatment and Chronic Breast Cancer-Related Lymphedema: Implications for Prospective Surveillance and Intervention From a Randomized Controlled Trial.

John Boyages^1,2,3, Frank A Vicini⁴, Behnaz Azimi Manavi⁵, Richelle L Gaw⁶, Louise A Koelmeyer¹, Sheila H Ridner⁷, Chirag Shah⁸

¹Australian Lymphoedema Education, Research, and Treatment Program, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.

²ICON Cancer Centre, Wahroonga, NSW, Australia.

³ANU Medical School, ANU College of Health and Medicine, Australian National University, Canberra, ACT, Australia.

⁴GenesisCare, Farmington Hills, MI.

⁵ImpediMed Limited, Pinkenba, QLD, Australia.

⁶IMPACT SRC, School of Medicine, Barwon Health, Faculty of Health, Deakin University, Geelong, VIC, Australia.

⁷Vanderbilt University School of Nursing, Nashville, TN.

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

PubMed PMC DOI PDF

Abstract

PURPOSE: The PREVENT randomized trial assessed progression to chronic breast cancer-related lymphedema (cBCRL) after intervention triggered by bioimpedance spectroscopy (BIS) or tape measurement (TM). This secondary analysis identifies cBCRL risk factors on the basis of axillary treatment. METHODS: Between June 2014 and September 2018, 881 patients received sentinel node biopsy (SNB; n = 651), SN…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.